Meeting At A GlanceJuly 11 — 14

American Society of Retina Specialists33rd Annual MeetingVienna, Austria

E V E N T L O C A T I O N S

Breakfast Included in your room rate at ASRS host hotels

General Sessions Austria Center Vienna Hall A, level 2

Retina Case Conference Austria Center Vienna Hall A, level 2

Breaks Austria Center Vienna Hall F, level 0

Lunches Austria Center Vienna Hall F, level 0

Welcome Reception Palais Liechtenstein

Scientific Posters Austria Center Vienna Hall F, level 0

PAT Survey Posters Austria Center Vienna Hall F, level 0

Exhibits Austria Center Vienna Hall F, level 0

Paper on Demand (POD) Kiosks Austria Center Vienna Hall F, level 0

3D Video Kiosks Austria Center Vienna Hall F, level 0

Film Festival Kiosks Austria Center Vienna Hall F, level 0

Instructional Courses Friday, July 10: InterContinental Wien Hotel Ballrooms 1-4 Johannesgasse 28, Wien

Monday, July 13 and Tuesday, July 14: Austria Center Vienna Hall A, level 2 and Hall E, level 0

Foundation Event Hotel Imperial reception and Musikverein

Gala Dinner Vienna City Hall

Speaker-Ready Room Room 2.31 level 2

Women in Retina (WinR) Lunch Austria Center Vienna Hall E, level 0

Young Physicians Section Lunch Austria Center Vienna Hall E, level 0

The American Society of Retina Specialists is accredited by the Accreditation Council forContinuing Medical Education to provide continuing medical education for physicians. The American Society of Retina Specialists designates this live activity for a maximumof 28.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the creditcommensurate with the extent of their participation in the activity.

Disclosure InformationIn accordance with the ACCME’s Standards for Commercial Support, ASRS required allindividuals controlling the content of this CME activity to disclose any relevant financialrelationships with commercial interests. ASRS implemented mechanisms to manageany conflicts of interest. Please see the program booklet (our mobile meeting site) fordisclosure information for all planners and teachers of this CME activity.

F R I D A Y , J U L Y 1 0 (pre-meeting programming)

1:00-5:15 PM Instructional Courses (InterContinental Wien Hotel)

1:00-2:15 PM Challenge the Masters, Ballroom Gabriela Lopezcarasa Hernandez, MD; Calvin E. Mein, MD; Section 1-2 Virgilio Morales-Canton, MD; Hugo Quiroz-Mercado, MD

1:00-2:15 PM Surgical Management of Complicated Retinal Detachments, Ballroom Alay S. Banker, MD Section 3-4 Faculty: Jay Chhablani, MD; Hemanth Murthy, MBBS, MD;

Manish Nagpal, MD, FRCS (UK); S. Natarajan, MD

2:30-3:45 PM Newer Advances in Vitreo-Retinal Surgeries: Tools and Ballroom Techniques, S. Natarajan, MD Section 1-2 Faculty: Alay S. Banker, MD; Ehab N. El-Rayes, MD, PhD;

Manish Nagpal, MD, FRCS (UK); Stanislao Rizzo, MD

2:30-3:45 PM Uveitis Controversies on the Blue Danube, Steven Yeh, MD Ballroom Faculty: Thomas A. Albini, MD; Howard F. Fine, MD, MHSc; Section 3-4 Purnima S. Patel, MD; Francesco Pichi, MD;

Sunil Srivastava, MD; Robert C. Wang, MD

4:00-5:15 PM Vitreoretinal Surgical Techniques (How Do I Do It?): Ballroom Video Panel, Ehab N. El-Rayes, MD, PhD Section 1-2 Faculty: Carl Claes, MD; Pravin U. Dugel, MD;

Tarek S. Hassan, MD; Kazuaki Kadonosono, MD; Carlos Mateo, MD; Yusuke Oshima, MD, PhD; Kourous A. Rezaei, MD; Stanislao Rizzo, MD; Malhar Soni, DO, MS, DNB, FRCS

4:00-5:15 PM Vitreoretinal Surgical Rounds. What Would Machemer Do? Ballroom 40 Years of Evolution, Tamer H. Mahmoud, MD, PhD Section 3-4 Faculty: Jose Garcia Arumi, MD, PhD; Susanne Binder, MD;

Sharon Fekrat, MD, FACS; Paul Hahn, MD, PhD; Akito Hirakata, MD; Glenn J. Jaffe, MD; Prithvi Mruthyunjaya, MD; Marco Mura, MD; Sengul Ozdek, MD; Stanislao Rizzo, MD; Cynthia Ann Toth, MD; Michael T. Trese, MD; Lejla Vajzovic, MD

A S R S A N N U A L M E E T I N G | 1

2 | 2 0 1 5

S A T U R D A Y , J U L Y 1 1

8:00-8:05 AM Welcome, Mark S. Humayun, MD, PhD

8:05-8:35 AM AMD Neovascular 1

8:05 Long-Term (60-month) Results of the Implantable Miniature Telescope, David Boyer, MD

8:13 Increased Risk of Surgical Complications, Postoperative Glaucoma, and Endophthalmitis With Cataract Surgery Following Intravitreal Injections, Paul Hahn, MD, PhD

8:21 Evaluating the Effects of VEGF-Trap Eye on Patients With Polypoidal Choroidal Vasculopathy: 3 Month Interim Analysis of VAULT Study, Joo Eun Lee, MD

8:29 Discussion

8:35-8:50 AM AMD Neovascular 1-Rapid Fire Papers

8:35 Ziv-aflibercept in Macular Disease, Ahmad Mansour, MD

8:40 Intravitreal Ziv-Aflibercept for Treatment of Wet Age-Related Macular Degeneration, Eduardo Rodrigues, MD

8:45 Discussion

8:50-9:20 AM AMD Neovascular 1-Expert Panel

Moderator: Timothy G. Murray, MD, MBA

8:50 Safety and Efficacy of RTH258 Delivered Via Intravitreal Injection or Microvolume Injection/Infusion for Neovascular Age-Related Macular Degeneration, Rishi Singh, MD

8:53 What Predicts the Development of Macular Atrophy in Wet AMD Patients Treated With Anti-VEGF?, Pravin Dugel, MD

8:56 Final Results From a Phase 2 Study of Squalamine Lactate Ophthalmic Solution 0.2% (OHR-102) in Neovascular Age-Related Macular Degeneration (AMD), Jeffrey Heier, MD

8:59 Overview of Conbercept Trials With Results of the LAMP (Treatment of Very-Low-Vision Age-Related Macular Degeneration Patients With Conbercept) Study, Peter Kaiser, MD

9:02 Acute Sterile Endophthalmitis Following Intravitreal Bevacizumab: Case Series in a Large Institution, Virgilio Morales-Canton, MD

9:05 Discussion

9:20-10:05 AM Break

10:05-10:45 AM International Panel, Kourous A. Rezaei, MD

10:45-11:05 AM AMD Non-neovascular 1-Rapid Fire Papers

10:45 Panmacular Subthreshold Diode Micropulse laser (SDM) Prophylaxis of Age-Related Macular and Inherited Photoreceptor Degenerations, Jeffrey Luttrull, MD

10:50 Nucleoside Reverse Transcriptase Inhibitors Possess Intrinsic Anti-Inflammatory Activity and Target Dry Age-Related Macular Gegeneration, Jayakrishna Ambati, MD

10:55 Generating Human Retinal Cells From Skin Biopsies of Patients With Advanced AMD, Lucian Del Priore, MD, PhD

11:00 Discussion

A S R S A N N U A L M E E T I N G | 3

11:05-11:35 AM AMD Non-neovascular-Expert Panel

Moderator: John T. Thompson, MD

11:05 Potential Public Health Impact of the Home Monitoring Device Evaluated in the Age-Related Eye Disease Study 2-Home Monitoring of the Eye Study, Carl Regillo, MD, FACS

11:08 Understanding Geographic Atrophy Disease Progression Through Visual Function Endpoints: The Lampalizumab Phase 3 Clinical Trial Program, Adnan Tufail, MBBS, MD, FRCOphth

11:11 Comparative Quantification of Geographic Atrophy Across Manual and Automated Grading Using Color, Red-Free, Autofluorescent, and OCT Images, Neil Bressler, MD

11:14 Intravitreal Erythropoietin in Eyes With Geographic Atropy Secondary to Age-Related Macular Degeneration, Stephen Sinclair, MD

11:17 Evaluation of Visual Acuity Measurements With Standard Luminance Compared With Low Luminance in Eyes With Geographic Atrophy From Age-Related Macular Degeneration, Diana Do, MD

11:35 AM-12:50 PM Lunch

12:50-1:15 PM Socioeconomics

12:50 Austrian Real Life Data of Intravitreal Injections Show No Benefit From Current Treatment, Gerhard Kieselbach, MD

12:58 The Commoditization of the Retinal Practice, Mark Nelson, MD, MBA

1:06 Utilization of the Dexamethasone Implant for Diabetic Macular Edema in US Clinical Practice: 2011-2014, Michael Singer, MD

1:11 Discussion

1:15-1:45 PM State of the ASRS

1:15 Retina PractiCare-Leveraging the Power of Claims Data, John Thompson, MD

1:23 Discussion

1:25 President’s Address, Tarek Hassan, MD

1:40 Discussion

1:45-2:45 PM Retinal Vascular Disease

1:45 Aflibercept for Radiation Retinopathy, Liliya Shevchenko, DO

1:53 Proteomic Analysis of Vitreous Humor in Retinal Vein Occlusion, Michael Koss, MD

2:01 What Step Changes in Diabetic Retinopathy (DR) Look Like: Photographic Cases of Improvement With Ranibizumab (RBZ), Baruch Kuppermann, MD, PhD

2:09 Squalamine Lactate Ophthalmic Solution for the Treatment of Macular Edema Secondary to Branch and Central Retinal Vein Occlusion. Final Data Analysis., John Wroblewski, MD

2:17 Discussion

2:24 Intravitreal Aflibercept Injection for Macular Edema Following Branch Retinal Vein Occlusion: Outcomes From the VIBRANT Study, Jennifer Lim, MD

2:29 The Impact of Cataract Surgery on Patients With Diabetic Macular Edema (DME) Receiving Ranibizumab, Andrew Moshfeghi, MD, MBA

4 | 2 0 1 5

2:34 Does Prior Treatment With Laser and/or Steroid Impact Outcomes With Ranibizumab (RBZ) Therapy for Diabetic Macular Edema (DME), J. Jumper, MD

2:39 Discussion

2:45-3:15 PM Break

3:15-4:15 PM Medical Case Conference

Moderators: Daniel F. Martin, MD and Neil M. Bressler, MD

Presenters:Netan Choudhry, MD, FRCS(C)Dilsher Dhoot, MDJorge Fortun, MDAnshul Goyal, MDTara McCannel, MD, PhDRodrigo Meirelles, MDJanusz Michalewski, MD, PhDQuan Dong Nguyen, MD, MScPaula Pecen, MDArmando Sandoval, MDDaraius Shroff, MS, FMRF, FRCS

4:15-5:15 PM Surgical Case Conference

Moderators: Carl C. Awh, MD and Kourous A. Rezaei, MD

Presenters:Hany Hamza, MDAshish Lall, MS, FRCS, DNB, MNAMS, FELLOW LVPEI, FNB RETINATatsushi Kaga, MD, PhDKamal Kishore, MD, MBBSColin McCannel, MDJeffrey Olson, MDSengul Ozdek, MDAleksandra Rachitskaya, MDMichael Seider, MDHomayoun Tabandeh, MDJohn Thompson, MDChristina Weng, MD, MBALeandro Zacharias, MD

7:00-10:00 PM Opening Reception

A S R S A N N U A L M E E T I N G | 5

S U N D A Y , J U L Y 1 2 , 2 0 1 5

8:00-8:35 AM Diabetic Retinopathy 1

8:00 Anti-VEGF Treatment of Diabetic Macular Edema in Clinical Practice: A Retrospective Study of Effectiveness and Patterns of Use, Kevin Blinder, MD

8:08 SSADA Assisted Angio-OCT Confirms Attenuation of Deep Capillary Macular Vascular Flow Index in Nonproliferative Diabetic Retinopathy, K. Chalam, MD, PhD, MBA, FRCS(C)

8:16 Randomized Trial of Prompt Panretinal Photocoagulation vs. Ranibizumab and Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy, Jennifer Sun, MD

8:24 Benefit-Risk Analysis of Phase 3 Clinical Trial Data Comparing Ranibizumab With Laser Treatment in Diabetic Macular Edema, Alan Cruess, MD, FRCS(C)

8:29 Discussion

8:35-9:05 AM Diabetic Retinopathy-Expert Panel

Moderator: Tarek S. Hassan, MD

8:35 Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results From the VISTA Trial, David Brown, MD

8:38 Comparative Effectiveness Randomized Clinical Trial of Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema, Carl Baker, MD

8:41 Comparative Effectiveness of Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for DME in a Randomized Trial: Treatment and Safety Outcomes, Andrew Antoszyk, MD

8:44 Ranibizumab (0.3 mg) for Persistent Diabetic Macular Edema (DME) After Recent, Frequent and Chronic Bevacizumab (ROTATE Trial): Six Month Results, Dennis Marcus, MD

8:47 Intravitreal Aflibercept Injection: Outcomes in DME Eyes With Very Limited Initial Anatomic Response in VISTA/VIVID Studies Through Weeks 52 and 100, Dante Pieramici, MD

8:50 Discussion

9:05-9:50 AM Break

9:50-11:25 AM Awards Ceremony

9:50 Pyron Award Introduction

9:55 Pryron Award, Gary W. Abrams, MD (lecture title TBD)

10:25 Founders Award Introduction

10:30 Founders Award, Richard F. Spaide, MD, Optical Coherence Tomography Angiography: The Reality Today and the Potential for the Future

11:00 Young Physicians Section (YPS), Crystal Apple Award

11:05 ASRS Presidents’ Retina Young Investigators Award

11:10 Yearly Progression Rates of Atrophic Lesions Measured by Fundus Autofluorescence in the Retrospective ProgStar Study, Hendrik P. Scholl, MD, MA

11:25 AM-12:40 PM Lunch

6 | 2 0 1 5

12:40-1:50 PM Retinal Detachment

12:40 Removing Swollen Hydrogel Explants (MIRAgel); Risk for Retinal Redetachment and Scleral Perforation in 467 Consecutive Cases, Niels Crama, MD

12:48 Adaptive Optics Imaging and Quantitative Analysis of Photoreceptors Following Repair of Rhegmatogenous Retinal Detachments, Meenakashi Gupta, MD

12:56 Outcomes and Complications of Densiron Intraocular Tamponade for Retinal Detachment Repairs: A Retrospective Chart Review, Amin Kherani, MD

1:04 Characterization of the Retinoschisis Outer Retinal Holes by Optical Coherence Tomography, Aleksandra Rachitskaya, MD

1:12 Discussion

1:18 Suprachoroidal Buckling Complications During Learning Curve, Flavio Rezende, MD, PhD

1:26 Subchoroidal Hemorrage After Blunt Trauma in Previous PK Ssing “Pole to Pole” Strategy: Overcoming a Taboo, Cesare Forlini, MD

1:34 Chandelier-Assisted Scleral Buckle for Repair of Primary Rhegmatogenous Retinal Detachment, Michael Seider, MD

1:39 Scleral Buckling With Wide Angled Endoillumination as a Surgical Educational Tool, Raja Narayanan, MD

1:44 Discussion

1:50-2:05 PM Surgical Techniques and Maneuvers

1:50 Multiple Posterior Vitreous Layers in Retinal Detachment and Diabetic Proliferative Retinopathy, James Folk, MD

1:58 Discussion

2:05-2:50 PM Instrumentation and Devices

2:05 Can Reading Speed or Video Scanning Laser Ophthalmoscopy Objectively Assess the Subjective Visual Improvement After Surgery for Vitreous Opacities?, Linda Lam, MD

2:13 Feasibility and Utility of Microscope-Integrated Intraoperative OCT for Vitreoretinal Surgery: The DISCOVER Study 1-Year Results, Justis Ehlers, MD

2:21 Fluid Dynamics of Vitrectomy Probes: The Quest for a Perfect Cutter, Tommaso Rossi, MD, EBOD

2:29 Discussion

2:34 Fluidics Analysis and Histopathological Findings With a New Prototype of Ultrasound Harmonics Vitrector (UHV): First Report, Paulo Stanga, MD

2:42 Pilot Study of Feasibility of Use of Experimental High Viscosity Silicone Oils, Alex Rubowitz, MD

2:47 Discussion

A S R S A N N U A L M E E T I N G | 7

2:50-3:20 PM Surgical Techniques and Maneuvers-Expert Panel

Moderator: Carl C. Awh, MD

2:50 Comparison of 25 Versus 27-Gauge for Vitreoretinal Surgery, Jared Nielsen, MD

2:53 Comparison of Iris-Sutured, Scleral-Sutured and Glued Intraocular Lens Implantation Techniques in Aphakic Patients, Gennady Landa, MD

2:56 Vitreomacular Traction Syndrome: Postoperative Functional and Anatomic Outcomes, Mauricio Maia, MD, PhD

2:59 Surgically Integrated 4-Dimensional, Swept-Source Optical Coherence Tomography (SSOCT) With Heads Up Display to Guide Vitreoretinal Surgery, Cynthia Toth, MD

3:02 Does Vitreous Status (Attached/Detached) Affect Visual Outcome in Patients Undergoing Vitrectomy for Floaters, Rubina Rahman, MBBS, FRCOpth, FRCS

3:05 Discussion

3:20-4:00 PM Break

4:00-4:50 PM Retinal Imaging in the Computer Age: The Future Is the Presence, Ursula Schmidt-Erfurth, MD

Faculty: Hrvoje Bogunovic, PhD; Bianca S. Gerendas, MD; Alessio Monturo, MSc; Sebastian M. Waldstein, MD

4:50-5:15 PM Revolutionary Retina, Suber S. Huang, MD, MBA

Faculty: Jeffrey S. Heier, MD; Darius M. Moshfeghi, MD; Stanislao Rizzo, MD

5:15-6:15 PM Scientific Posters & Exhibit Hall Reception

8 | 2 0 1 5

M O N D A Y , J U L Y 1 3

8:00-9:20 AM AMD Neovascular 2

8:00 Age-Related Macular Degeneration and Aspirin Use, Kent Small, MD

8:08 Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of AMD Treatments Trials (CATT), Thomas Ciulla, MD

8:16 Prospective, Multicenter Investigation of Aflibercept Treat and Extend Therapy for Neovascular Age-Related Macular Degeneration, Francis DeCroos, MD

8:24 Discussion

8:29 How Do Large Pigment Epithelial Detachments Respond to Ranibizumab Treatment in Wet AMD Patients?, David Eichenbaum, MD

8:37 Factors Influencing Dose Accuracy and Variation of Anti-VEGF Drug Injections, Raymond Iezzi, MD, MS

8:45 En Face Optical Coherence Tomography Imaging of Polypoidal Choroidal Vasculopathy (PCV) Diagnosed With Indocyanine Green (ICG) Angiography, Gregg Kokame, MD, MMM

8:53 Discussion

8:58 Long-Term Vision and Anatomic Outcomes for Neovascular Age-Related Macular Degeneration (NVAMD) Patients in the Anti-VEGF Era, George Parlitsis, MD

9:06 Fluorescein Angiography Features Predictive of Polypoidal Choroidal Vasculopathy: A Post-hoc Analysis From the Randomized Controlled EVEREST Study, Colin Tan, MBBS, MMed (Ophth), FRCSEd (Ophth)

9:14 Discussion

9:20-9:40 AM AMD Neovascular 2-Rapid Fire Papers

9:20 Gene Therapy: The Next Frontier in the Management of Neovascular Age-Related Macular Degeneration (nAMD) and Other Acquired and Inherited Disorders, Szilard Kiss, MD

9:25 Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: 5-Year Results of the PACORES Group, Lihteh Wu, MD

9:30 The Top 10 Practical Pearls From the HARBOR Trial of Ranibizumab in Neovascular (wet) Age-Related Macular Degeneration (wAMD), Victor Gonzalez, MD

9:35 Discussion

9:40-10:30 AM Break

10:30-10:50 AM Pediatric Retina-ROP

10:30 Telemedicine Diagnosis of Plus Disease in Retinopathy of Prematurity: Accuracy of Expert Versus Computer-Assisted Quantitative Vascular Analysis, Ashkan Abbey, MD

10:38 Neurodevelopmental Outcomes in Infants With Retinopathy of Prematurity and Bevacizumab Treatment, Wei-Chi Wu, MD, PhD

10:46 Discussion

A S R S A N N U A L M E E T I N G | 9

10:50-11:20 AM Pediatric Retina-ROP-Expert Panel

Moderator: Philip J. Ferrone, MD

10:50 Fundus Pigmentation as a Risk Factor for Development of Retinopathy of Prematurity, Audina Berrocal, MD

10:53 Fluorescein Angiography for the Diagnosis and Management of Retinopathy of Prematurity, Michael Klufas, MD

10:56 Retinal Detachments After Intravitreal Anti-VEGF Injections for Retinopathy of Prematurity, Antonio Capone, MD

10:59 Local and Systemic Adverse Events After Intravitreal Bevacizumab in the Treatment of Retinopathy of Prematurity in a Nine Year Period, Maria Martinez-Castellanos, MD

11:02 Newborn Infant Global Universal Eye Screen Testing (GUEST) Study: Validation of Technique Approach, Darius Moshfeghi, MD

11:05 Discussion

11:20 AM-12:00 PM Ocular Oncology

11:20 Application of Results of Cytopathological Analysis and Gene Expression Profile in Clinically Diagnosed Posterior Uveal Melanomas Evaluated by FNAB, Zelia Correa, MD, PhD

11:28 Iodine-125 Brachytherapy for Extra-Large Choroidal Melanomas: Benefit of Vitrectomy and Silicone Oil on Visual Acuity, Tara McCannel, MD, PhD

11:36 Peripheral Retinal Perfusion Correlates With Radiation Retinopathy Status Following I-125 Brachytherapy for Uveal Melanoma, Prithvi Mruthyunjaya, MD

11:44 Intravitreal Pharmacotherapy for Radiation Maculopathy (IRM Study): 5-year Follow-Up Detailing Treatment Extension and Enhanced Outcomes, Timothy Murray, MD, MBA

11:52 Discussion

12:00-1:15 PM Lunch

1:15-2:15 PM Inflammatory and Infectious Diseases

1:15 Injectable Long-Acting Intravitreal Floucinolone Acetonide Implant to Treat Non-infectious Intermediate, Posterior or Panuveitis, Glenn Jaffe, MD

1:23 Treatment of Cytomegalovirus (CMV) Retinitis With Third Party Donor-Derived CMV-Specific Cytotoxic T-lymphocytes, Mrinali Gupta, MD

1:31 The Utility of 2z Ultra-Wide Fluorescein Angiography in the Management of Uveitis Patients, Sunil Srivastava, MD

1:39 Analyses of SAVE-2: A Phase 2 Study to Assess the Safety and Efficacy of Two Doses of Intravitreal Sirolimus in Patients With Noninfectious Uveitis, Quan Nguyen, MD, MSc

1:47 Discussion

1:53 Intravitreal Sirolimus Monotherapy Reduces the Corticosteroid Treatment Burden in Subjects With NIU of the Posterior Segment: SAKURA Study 1 Results, Pauline Merrill, MD

10 | 2 0 1 5

1:58 The Importance of Using Povidone-Iodine and Elimination of Topical Antibiotics for Intravitreous Injections: Update From the DRCR.net, Abdhish Bhavsar, MD

2:03 Varicella Zoster Virus (VZV) Antigen Presence and Distribution in Giant Cell Arteritis (GCA) Positive Temporal Artery (TA) Biopsies, Naresh Mandava, MD

2:08 Discussion

2:15-2:35 PM Hereditary Retinal Disease & Genetics

2:15 Effectiveness of Dexamethasone Intravitreal Implant in Refractory Macular Edema Due to Retinitis Pigmentosa, Cem Kucukerdonmez, MD

2:23 Whole Exome Sequencing Identifies Rare Genetic Variants in Age-Related Macular Degeneration Patients, Eran Pras, MD

2:31 Discussion

2:35-3:10 PM Pharmacology

2:35 Pericentral Hydroxychloroquine Retinopathy in Korean Patients, Young Hee Yoon, MD

2:43 Anti-Angiogenics in Iatrogenic Choroidal Neovascularization in Central Serous Chorioretinopathy, Jay Chhablani, MD

2:48 MEK Inhibitor-Associated Subretinal Fluid, Marissa Weber, MD

2:53 Bilateral Macular Neurosensory Retinal Detachment Associated With MEK Inhibitor Use for Metastatic Cancer: A Case Series and Review of the Literature, Seenu Hariprasad, MD

2:58 PRN Dexamethasone Implant for Macular Edema, Michel Farah, MD, PhD

3:03 Discussion

3:10-4:00 PM Break

4:00 4:50 PM RETINAWS: When the Going Gets Tough, the Tough Get Going, Challenging Cases in Vitreoretinal Surgery, Kourous Rezaei, MD

Faculty: Jose Garcia Arumi, MD, PhD; Susanne Binder, MD; Stratos V. Gotzaridis, MBBS, MD; Nikoloz Labauri, MD, FVRS; Kirk H. Packo, MD, FACS; Grazia Pertile, MD; Homayoun Tabandeh, MD

A S R S A N N U A L M E E T I N G | 11

T U E S D A Y , J U L Y 1 4

8:00-8:25 AM Business Meeting-ASRS Members Only

8:25-8:30 AM PAT Survey Presentation

8:30-10:15 AM Diabetic Retinopathy 2

8:30 Rescue Treatment With Intravitreal Aflibercept Injection in Patients With Diabetic Macular Edema (DME) Randomized to Laser in VISTA and VIVID, Charles Wykoff, MD, PhD

8:38 Systemic Safety of Intensive Use of Intravitreal Anti-VEGF Agents for Diabetic Macular Edema, Robert Avery, MD

8:46 Switching Treatment for DME From Bevacizumab to Ranibizumab: Who is Likely to Benefit From the Switch?, Gabriel Katz, MD

8:54 Discussion

8:59 Vitrectomy in the Management of Diabetic Macular Edema in Treatment-Naïve Patients, Jerzy Nawrocki, MD, PhD

9:07 The Cardiovascular and Cerebrovascular Safety Profile of Intravitreal Ranibizumab (RBZ) in DME: A Pooled Analysis of 6 Phase II/III Clinical Trials, Marco Zarbin, MD, PhD

9:15 Discussion

9:20 Prospective, Randomized, Subject Masked Study of Intravitreal Bevacizumab Versus Dexamethasone Implant in the Treatment of Diabetic Macular Edema, Raj Maturi, MD

9:25 Targeted Retinal Photocoagulation (TRP) vs Vitrectomy With ILM Peeling to Treat Recalcitrant Diabetic Macular Edema-A Comparative Study, Subhendu Boral, MBBS, MD (AIIMS), DNB (OPHTHALMOLOGY)

9:30 Visual and Anatomic Outcomes After Addition of Triamcinolone Acetonide to Anti-VEGF Compared to Anti-VEGF Monotherapy for Diabetic Macular Edema, Petros Carvounis, MD, FRCSC

9:35 Discussion

9:40 PASCAL Panretinal Photocoagulation (PRP) Versus ETDRS-PRP With Intravitreal Ranibizumab (IVR) Versus IVR Only for Proliferative Diabetic Retinopathy, Rodrigo Jorge, MD

9:45 Vitreous Levels of Endolthelial Nitric Oxide Synthase S1177 are Inversely Related to Severity of Diabetic Macular Edema, Matthew Katz, MD

9:50 Discussion

9:55 Intravitreal Bevacizumab Alone or Combined With 1mg Triamcinolone in Diabetic Macular Edema. A Randomized Clinical Trial, Mohammad Riazi, MD

10:00 The Cost-Effectiveness of Anti-VEGF Treatments for Diabetic Macular Edema, Nancy Holekamp, MD

10:05 Prevalence of Diabetic Macular Edema Based on Monocular Fundus Photography vs Optical Coherence Tomography, Susan Bressler, MD

10:10 Discussion

10:15-11:00 AM Break

12 | 2 0 1 5

11:00 AM-12:00 PM Macular Pucker-Epiretinal Membrane

11:00 Efficacy and Safety of Pneumatic Vitreolysis, Ocriplasmin and Vitrectomy for Symptomatic Vitreomacular Adhesions: A Case Series and Meta-Analysis, Jorge Arroyo, MD, MPH

11:08 Results of Using Membrane Blue Dual in Epiretinal Membrane and Macular Hole Surgery Without Face Down Position, Boris Bajaire, MD

11:16 25-Gauge Pars Plana Vitrectomy (PPV) for Myopic Foveoschisis (MF), Francesco Boscia, MD

11:24 Discussion

11:30 Epiretinal Membrane Peeling in Patients With Good Starting Pre-op Vision, Nicholas Chinskey, MD

11:38 Optical Coherence Tomography Assisted Predictors of Visual Outcome in Epiretinal Membrane Removal, Srinivas Joshi, MD

11:46 Swept-Source OCT correlations Between Retina and Choroid Before and After Vitrectomy for Epiretinal Membranes, Janusz Michalewski, MD, PhD

11:54 Discussion

12:00-1:15 PM Lunch

1:15-2:30 PM Macular Holes

1:15 Initial Outcomes Following Intravitreal Ocriplasmin for Treatment of Symptomatic Vitreomacular Adhesion: A Canada-Wide Study, Netan Choudhry, MD, FRCS(C)

1:23 Intravitreal Perfluoropropane Gas (C3F8) Versus Ocriplasmin for the Treatment of Vitreomacular Traction (VMT), Nathan Steinle, MD

1:31 The Combined Tractional-Hydration Theory of Idiopathic Macular Holes, Ronald Gentile, MD

1:39 Discussion

1:44 Pneumatic Vitreolysis for Treatment of Focal Vitreomacular Traction and Early Small Macular Holes, Calvin Mein, MD

1:52 Subretinal BSS injection: A Technique for the Treatment of Chronic Persistent Macular Holes, Rajeev Muni, MD, MSC, FRCSC

2:00 Discussion

2:05 The Aborted Macular Hole: An Optical Coherence Tomography Study, Steven Agemy, MD

2:10 Correlation of Foveal Microstructure and Lucencies Assessed Using High-Density SDOCT Radial Scans With Visual Recovery Following Macular Hole Surgery, Dilraj Grewal, MD

2:15 The Outer Choroidoscleral Boundary in Full-Thickness Macular Holes Before and After Surgery-A Swept Source OCT Study, Zofia Michalewska, MD, PhD

2:20 Infracyanine Green Versus Brillant Blue G in Macular Hole Surgery, Christiane Falkner-Radler, MD

2:25 Discussion

2:30-3:15 PM Imaging-Digital-Angiography

2:30 Comparison of Choroidal Thickness in Unilateral Central Serous Chorioretinopathy (CSCR) in Acute and Resolved Phases Versus Normal Control Eyes, Alay Banker, MD

A S R S A N N U A L M E E T I N G | 13

2:38 Correlation of Vitreomacular Traction With Foveal Thickness, Subfoveal Choroidal Thickness and Vitreomacular Angle, Igor Kozak, MD, PhD

2:43 SD-OCT Findings of Presence of Spherical Hyperreflective Bodies in Sub Silicone Oil Space and Visual Outcomes in Eyes Undergoing Silicone Oil Removal, Manish Nagpal, MD, FRCS (UK)

2:48 Discussion

2:54 Efficacy of Intravitreal Bevacizumab in Eyes With Myopic Choroidal Neovascularization Without Intraretinal or Subretinal Fluid on Spectral-domain OCT, Randee Miller, MD

2:59 Diabetic Retinopathy (DR) Severity and Predominantly Peripheral DR Lesions are Associated With Nonperfusion on Ultrawide Field Angiography, Paolo Antonio Silva, MD

3:04 High Resolution (23x35 Microns), Real-Time Anterior Segment B-scan Ultrasonopgraphy for the Posterior Segment Surgeon, Yale Fisher, MD

3:09 Discussion

3:15-3:45 PM Imaging-Digital-Angiography: Expert Panel

Moderator: John S. Pollack, MD

3:15 OCT Angiographic Perfusion Mapping of Macular Vascularity in Diabetic and Normal Subjects, Richard Rosen, MD, DSc(Hon)

3:18 Six-Year Utilization Patterns of Ophthalmic Imaging Tests In Patients With Retinal Diseases, Jorge Fortun, MD

3:21 Prognostic Value of Optical Coherence Tomography Based Classification of Myopic Choroidal Neovascularization, Roberto Gallego-Pinazo, MD, PhD, DiSSO

3:24 Optical Coherence Tomography Angiography in Retinal Disease, Amir Kashani, MD PhD

3:27 Ultra-Widefield Imaging of the Peripheral Retinal Vasculature in Normal Subjects, Srinivas Sadda, MD

3:30 Discussion

3:45-4:15 PM Break

4:15-5:05 PM ASRS Research and Development Committee Symposium: Clinical Trials “Unplugged” Real, Practical Questions and Answers, Pravin Dugel, MD

Faculty: Carl C. Awh, MD; David S. Boyer, MD; David M. Brown, MD; Antonio Capone, MD; Tarek S. Hassan, MD; Jeffrey S. Heier, MD; J. Michael Jumper, MD; Peter K. Kaiser, MD; Baruch D. Kuppermann, MD, PhD; Timothy G. Murray, MD, MBA; John S. Pollack, MD; Carl D. Regillo, MD, FACS; Philip J. Rosenfeld, MD, PhD; John T. Thompson, MD

4:15-5:05 PM Incorporating Argus II Retinal Prosthesis into Practice: Surgical Candidate Selection, Surgical Procedure, and Post-implant Course, Ninel Gregori, MD

Faculty: J. Fernando Arevalo, MD, FACS; Mark S. Humayun, MD, PhD; Stanislao Rizzo, MD

7:00-11:30 PM Closing Dinner